ASLAN (ASLN) Pushes Higher in Pre-Market Trading for August 5

Equities Staff  |

ASLAN Pharmaceuticals Ltd - ADR (NASDAQ:ASLN) has already gained $0.04 in early trading Friday.

After closing the previous trading session at $0.51, ASLAN has moved 7.84% higher ahead of market open.

The company is up 13.68% over the last 5 days.

Today could shape up to be an interesting day for ASLAN investors.

For technical charts, analysis, and more on ASLAN Pharmaceuticals Ltd - ADR visit the company profile.

Pre-market prices and movements as of 07:06:23 est.

About ASLAN Pharmaceuticals Ltd - ADR

ASLAN Pharmaceuticals, a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the appointment of Kathleen M. Metters, PhD, as an independent director. Dr Metters has more than 30 years’ experience in the discovery and development of novel therapies for the treatment of chronic diseases, including autoimmune diseases. Dr Metters is a member of several boards, including Hemoshear Therapeutics LLC and Pharmaxis Ltd (ASX:PSX). Most recently, she was Chief Executive Officer and President of Lycera Corp, where she spearheaded a robust pipeline of proprietary and partnered immune modulator programs.

To get more information on ASLAN Pharmaceuticals Ltd - ADR and to follow the company's latest updates, you can visit the company's profile page here: ASLAN Pharmaceuticals Ltd - ADR's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

The Strong Dollar Is a Problem for Stocks
3 Ways Finance Teams Can Navigate Inflation Through Automation



Market Movers

Sponsored Financial Content